The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Treatment of 200 Locally Advanced (Stage III) Pancreatic Adenocarcinoma Patients With Irreversible Electroporation: Safety and Efficacy
Abstract
In Brief Objectives: Ablative therapies have been increasingly utilized in the treatment of locally advanced pancreatic cancer (LAPC). Irreversible electroporation (IRE) is an energy delivery system, effective in ablating tumors by inducing irreversible membrane destruction of cells. We aimed to demonstrate efficacy of treatment with IRE as part of multimodal treatment of LAPC. Methods: From July 2010 to October 2014, patients with radiographic stage III LAPC were treated with IRE and monitored under a multicenter, prospective institutional review board–approved registry. Perioperative 90-day outcomes, local failure, and overall survival were recorded. Results: A total of 200 patients with LAPC underwent IRE alone (n = 150) or pancreatic resection plus IRE for margin enhancement (n = 50). All patients underwent induction chemotherapy, and 52% received chemoradiation therapy as well for a median of 6 months (range, 5–13 months) before IRE. IRE was successfully performed in all patients. Thirty-seven percent of patients sustained complications, with a median grade of 2 (range, 1–5). Median length of stay was 6 days (range, 4–36 days). With a median follow-up of 29 months, 6 patients (3%) have experienced local recurrence. Median overall survival was 24.9 months (range: 4.9–85 months). Conclusions: For patients with LAPC (stage III), the addition of IRE to conventional chemotherapy and radiation therapy results in substantially prolonged survival compared with historical controls. These results suggest that ablative control of the primary tumor may prolong survival. We aimed to demonstrate efficacy of treatment with Irreversible Electroporation as part of multimodal treatment of locally advanced pancreatic cancer. For patients with locally advanced pancreatic cancer (stage III), the addition of irreversible electroporation to conventional chemotherapy and radiation therapy results in substantially prolonged survival compared to historical controls. These results suggest that ablative control of the primary tumor may prolong survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Callery, M. P., Chang, K. J., Fishman, E. K., Talamonti, M. S., William Traverso, L., & Linehan, D. C. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0408-6 · Cited by 902
Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy
Varadhachary, G. R., Tamm, E. P., Abbruzzese, J. L., Xiong, H. Q., Crane, C. H., Wang, H., Lee, J. E., Pisters, P. W. T., Evans, D. B., & Wolff, R. A. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.08.011 · Cited by 876
Ferrone, C. R., Marchegiani, G., Hong, T. S., Ryan, D. P., Deshpande, V., McDonnell, E. I., Sabbatino, F., Santos, D. D., Allen, J. N., Blaszkowsky, L. S., et al. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000867 · Cited by 842
Herman, J. M., Chang, D. T., Goodman, K. A., Dholakia, A. S., Raman, S. P., Hacker‐Prietz, A., Iacobuzio‐Donahue, C. A., Griffith, M. E., Pawlik, T. M., Pai, J. S., et al. (2015) · Cancer · doi:10.1002/cncr.29161 · Cited by 542
An electronic application for rapidly calculating Charlson comorbidity score
Hall, W. H., Ramachandran, R., Narayan, S., Jani, A. B., & Vijayakumar, S. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-94 · Cited by 532
Gourgou-Bourgade, S., Bascoul-Mollevi, C., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.4869 · Cited by 501
Cannon, R., Ellis, S., Hayes, D., Narayanan, G., & Martin, R. C. G. (2013) · Journal of Surgical Oncology · doi:10.1002/jso.23280 · Cited by 338
Self-citationMartin, R. C. G., McFarland, K., Ellis, S., & Velanovich, V. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2736-1 · Cited by 306
Self-citation
Cited by
A Comprehensive Review of Calcium Electroporation—A Novel Cancer Treatment Modality
Frandsen, S. K., Vissing, M., & Gehl, J. (2020) · Cancers · doi:10.3390/cancers12020290 · Cited by 132
Difference in Membrane Repair Capacity Between Cancer Cell Lines and a Normal Cell Line
Frandsen, S. K., McNeil, A. K., Novak, I., McNeil, P. L., & Gehl, J. (2016) · The Journal of Membrane Biology · doi:10.1007/s00232-016-9910-5 · Cited by 53
Present and future of metal nanoparticles in tumor ablation therapy
Lou, W., Xie, L., Xu, L., Xu, M., Xu, F., Zhao, Q., & Jiang, T. (2023) · Nanoscale · doi:10.1039/d3nr04362b · Cited by 33
Metadata
- Authors
- Martin, R. C. G., Kwon, D., Chalikonda, S., Sellers, M., Kotz, E., Scoggins, C., McMasters, K. M., & Watkins, K.
- Venue
- Annals of Surgery
- Published
- 2015-09
- Volume
- 262
- Issue
- 3
- Pages
- 486-494
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W2122041824
- Cited by
- 417
- References
- 26
- FWCI
- 17.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of 200 Locally Advanced (Stage III) Pancreatic Adenocarcinoma Patients With Irreversible Electroporation: Safety and Efficacy. https://app.cochat.ai/papers/10.1097/sla.0000000000001441
- The paper
- Martin, R. C. G., Kwon, D., Chalikonda, S., Sellers, M., Kotz, E., Scoggins, C., McMasters, K. M., & Watkins, K. (2015). Treatment of 200 Locally Advanced (Stage III) Pancreatic Adenocarcinoma Patients With Irreversible Electroporation: Safety and Efficacy. Annals of Surgery. https://doi.org/10.1097/sla.0000000000001441
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.